Majedie Asset Management Ltd cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 27.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,741 shares of the biopharmaceutical company’s stock after selling 20,618 shares during the quarter. Majedie Asset Management Ltd’s holdings in Gilead Sciences were worth $3,850,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Welch Investments LLC purchased a new stake in Gilead Sciences in the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences in the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in Gilead Sciences in the 3rd quarter worth approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $147,000. Finally, Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Institutional investors and hedge funds own 77.83% of the company’s stock.
GILD has been the topic of a number of research analyst reports. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Barclays reissued an “overweight” rating and issued a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Mizuho set a $95.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, February 5th. Finally, Leerink Swann reissued a “market perform” rating and issued a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $88.61.
In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $80.93, for a total value of $472,064.69. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gayle E. Wilson sold 60,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the sale, the director now directly owns 182,258 shares in the company, valued at approximately $14,201,543.36. The disclosure for this sale can be found here. In the last three months, insiders sold 430,268 shares of company stock worth $34,074,395. Insiders own 1.30% of the company’s stock.
Gilead Sciences stock opened at $79.74 on Monday. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The company has a market cap of $104,456.84, a price-to-earnings ratio of 22.91, a P/E/G ratio of -1.83 and a beta of 1.24.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.70 EPS. research analysts forecast that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date of this dividend is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is 65.52%.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Holdings Cut by Majedie Asset Management Ltd” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/03/19/gilead-sciences-inc-gild-holdings-cut-by-majedie-asset-management-ltd.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.